VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Vaccine Mechanisms
Vaximmutordb
Vaxism
Vaxar
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UMMS Logo

Vaccine Detail

Melanoma DNA vaccine xenogeneic DNA encoding murine tyrosinase
Vaccine Information
  • Vaccine Ontology ID: VO_0004465
  • Type: DNA vaccine
  • Status: Research
  • Host Species as Laboratory Animal Model: Dog
  • Tyrosinase from Mouse gene engineering:
    • Type: DNA vaccine construction
    • Description: Vector pING expressed murine tyrosinase (Manley et al., 2011).
    • Detailed Gene Information: Click Here.
  • Vector: pING plasmid vector (Manley et al., 2011)
  • Immunization Route: Intramuscular injection (i.m.)
Host Response

Dog Response

  • Vaccine Immune Response Type: VO_0000286
  • Efficacy: Overall median survival time (MST) for dogs treated with loco-regional control and xenogeneic DNA vaccine was 476 days with a 1-year survival rate of 63%. The xenogeneic murine tyrosinase DNA vaccine was safe and appears effective when used in conjunction with local and regional disease control (Manley et al., 2011).
References
Manley et al., 2011: Manley CA, Leibman NF, Wolchok JD, Rivière IC, Bartido S, Craft DM, Bergman PJ. Xenogeneic murine tyrosinase DNA vaccine for malignant melanoma of the digit of dogs. Journal of veterinary internal medicine / American College of Veterinary Internal Medicine. 2011; 25(1); 94-99. [PubMed: 21143299].